Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Current Status of Pediatric Labeling in China and the near Future Efforts Needed for the Country.

Li Z, Wang Y, Wu D, Gao X, Wang Z.

Front Pediatr. 2014 Mar 26;2:17. doi: 10.3389/fped.2014.00017. eCollection 2014 Mar 26.

2.

Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA.

Bajcetic M, Kearns GL, Jovanovic I, Brajovic M, van den Anker JN.

Curr Pharm Des. 2015;21(39):5668-73. Review.

PMID:
26323413
3.

[Survey on common pediatric drugs for renal diseases].

Ye WQ, Liang Y, Cui YM, Ding J.

Zhonghua Er Ke Za Zhi. 2013 Dec;51(12):888-91. Chinese.

PMID:
24495757
4.

Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups.

Giacoia GP, Taylor-Zapata P, Mattison D.

Clin Ther. 2008 Nov;30(11):2097-101. doi: 10.1016/j.clinthera.2008.11.017.

PMID:
19108797
5.
6.

Pediatric off-label drug use in China: risk factors and management strategies.

Zhang L, Li Y, Liu Y, Zeng L, Hu D, Huang L, Chen M, Lv J, Yang C.

J Evid Based Med. 2013 Feb;6(1):4-18. doi: 10.1111/jebm.12017.

PMID:
23557523
7.

Unlicensed and off-label drug use: issues and recommendations.

Conroy S.

Paediatr Drugs. 2002;4(6):353-9.

PMID:
12038871
8.

Pharmaceutical counseling: Between evidence-based medicine and profits.

Egorova SN, Akhmetova T.

Int J Risk Saf Med. 2015;27 Suppl 1:S87-8. doi: 10.3233/JRS-150701.

PMID:
26639727
9.

Fighting trafficking of falsified and substandard medicinal products in Russia.

Fayzrakhmanov NF.

Int J Risk Saf Med. 2015;27 Suppl 1:S37-40. doi: 10.3233/JRS-150681.

PMID:
26639702
10.

Chinese herbal medicines for unexplained recurrent miscarriage.

Li L, Dou L, Leung PC, Chung TK, Wang CC.

Cochrane Database Syst Rev. 2016 Jan 14;(1):CD010568. doi: 10.1002/14651858.CD010568.pub2. Review.

PMID:
26760986
11.

Future development of global regulations of Chinese herbal products.

Fan TP, Deal G, Koo HL, Rees D, Sun H, Chen S, Dou JH, Makarov VG, Pozharitskaya ON, Shikov AN, Kim YS, Huang YT, Chang YS, Jia W, Dias A, Wong VC, Chan K.

J Ethnopharmacol. 2012 Apr 10;140(3):568-86. doi: 10.1016/j.jep.2012.02.029. Epub 2012 Feb 25. Review.

12.

Pediatric drug formulations: a review of challenges and progress.

Ivanovska V, Rademaker CM, van Dijk L, Mantel-Teeuwisse AK.

Pediatrics. 2014 Aug;134(2):361-72. doi: 10.1542/peds.2013-3225. Epub 2014 Jul 14. Review.

13.

Poor formulation information in published pediatric drug trials.

Standing JF, Khaki ZF, Wong IC.

Pediatrics. 2005 Oct;116(4):e559-62.

PMID:
16199684
14.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
16.

Dosing information in a standard drug reference: are pediatrics still therapeutically neglected?

Permala J, Hassali MA, Awaisu A, Shafie AA.

Pediatr Int. 2010 Apr;52(2):290-5. doi: 10.1111/j.1442-200X.2009.02958.x. Epub 2009 Sep 7.

PMID:
19744224
17.

European perspectives on pediatric formulations.

Breitkreutz J.

Clin Ther. 2008 Nov;30(11):2146-54. doi: 10.1016/j.clinthera.2008.11.016.

PMID:
19108802
18.

Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.

Brion F, Nunn AJ, Rieutord A.

Acta Paediatr. 2003 Apr;92(4):486-90.

PMID:
12801118
19.

Essential medicines for children in Armenia.

Kazaryan I, Vardanyan L.

Int J Risk Saf Med. 2015;27 Suppl 1:S43-4. doi: 10.3233/JRS-150682.

PMID:
26639704
20.

Developing drug formularies for the "National Medical Holding" JSC.

Akhmadyar NS, Khairulin BE, Amangeldy-Kyzy S, Ospanov MA.

Int J Risk Saf Med. 2015;27 Suppl 1:S51-2. doi: 10.3233/JRS-150686.

PMID:
26639709

Supplemental Content

Support Center